News: BNF correction
The section on bisphosphonates in the latest edition of the British National Formulary (no. 42) contains a misleading statement in its discussion of disodium etidronate.
It states that disodium etidronate can impair bone mineralisation (section 6.6.2, p364). Although this is true when giving the drug continously to treat Pagets disease, the text does not say that it is of little relevance when the drug is used intermittently for the treatment and prevention of osteoporosis.
The electronic versions of the BNF have been corrected and the text will be reworded for the next edition of the book.
Citation: Electronicjuice URI: 20005031
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Electronicjuice, and is a leading provider of authoritative pharmaceutical information used throughout the world.